Background: The Solid Tumor Problem Isn’t the Tumor; It’s The Environment

CAR T-cell therapy has reshaped the treatment landscape of hematologic malignancies, delivering deep and often durable responses across multiple disease settings.¹ In solid tumors, however, progress has been far more limited. This disparity is not due to a failure of CAR T-cell engineering itself but rather reflects the fundamentally different biological context in which these therapies must operate.

The dominant barrier is the tumor microenvironment (TME)—a highly organized, immunosuppressive ecosystem that effectively neutralizes incoming immune effectors before they can meaningfully engage tumor cells. Among the most influential components of this environment are tumor-associated macrophages (TAMs). Frequently comprising a substantial fraction of tumor-infiltrating immune cells, TAMs suppress cytotoxic T-cell activity, promote angiogenesis, facilitate metastatic spread, and contribute to resistance across both checkpoint inhibition and adoptive cell therapy platforms.^2,3

Single-cell transcriptomic analyses have further clarified that these immunosuppressive TAM subsets are not random but instead share conserved molecular features across tumor types. In particular, expression of FOLR2 and TREM2 has emerged as a defining characteristic of pro-tumor macrophage populations in high-grade serous ovarian cancer, pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal cancer.^4,5 Importantly, these markers are relatively restricted in normal tissue macrophages, providing a potential therapeutic window.

Prior attempts to target TAMs have yielded important insights but limited clinical success. CSF1R inhibitors, for example, were effective at reducing macrophage populations but failed to translate into meaningful tumor responses.^6,7 These experiences highlighted a key limitation: depletion alone does not restore immune function. In the absence of active reprogramming, the TME simply repopulates with cells of similar suppressive phenotype.

The work by Mateus-Tique and colleagues reframes this challenge. Rather than viewing TAMs solely as a population to eliminate, they approach the TME as a dynamic system—one that can be actively reshaped.⁸

The Study: Engineering the Immune Ecosystem

In this Cancer Cell report, Mateus-Tique and colleagues describe a CAR T-cell platform built on two coordinated principles: targeted elimination of immunosuppressive TAMs via FOLR2 or TREM2, and localized delivery of IL-12 to reshape the surrounding immune landscape.⁸

The selection of FOLR2 and TREM2 as targets is intentional. These markers are consistently enriched on suppressive TAM subsets across multiple tumor types and are comparatively limited in normal macrophage populations.^4,5 By directing CAR T cells toward this compartment, the strategy avoids reliance on tumor-specific antigens—an important advantage in cancers characterized by antigen heterogeneity and immune escape.

IL-12 serves as the functional payload. Its capacity to drive IFN-γ production, activate cytotoxic lymphocytes, and polarize macrophages toward an immunostimulatory phenotype makes it particularly well suited for this application.⁹ At the same time, systemic IL-12 administration has historically been limited by significant toxicity.¹⁰ The approach used here—CAR-dependent, spatially restricted cytokine delivery—is designed to capture the immunologic benefit of IL-12 while minimizing systemic exposure.

Conceptually, the architecture is straightforward: remove the dominant suppressive population, then guide the immune system toward a more favorable equilibrium.

Key Findings

Depletion Alone Is Insufficient—IL-12 Establishes the Therapeutic Threshold

Unarmed anti-FOLR2 CAR T cells trafficked effectively to tumor sites and achieved selective macrophage depletion. Despite this, anti-tumor activity was limited, with eventual tumor progression.⁸ This finding closely parallels prior clinical experience with macrophage-targeted therapies and reinforces the notion that depletion alone is mechanistically incomplete.

The addition of IL-12 fundamentally altered this outcome. In the ID8-BV BRCA1-deleted ovarian cancer model—an aggressive and clinically relevant system—control animals succumbed by day 35. In contrast, treatment with IL-12–armored anti-FOLR2 CAR T cells, administered at a dose of just 10⁵ cells and without lymphodepletion, resulted in rapid tumor regression and prolonged survival beyond 95 days, with complete remissions observed.⁸

To further refine the therapeutic window, the investigators developed a destabilization domain (DD) version of IL-12, enabling modulation of cytokine output. This approach maintained efficacy while improving tolerability, with no significant weight loss or hepatotoxicity observed. Notably, hepatic FOLR2⁺ Kupffer cells were spared at therapeutic doses, suggesting a degree of functional specificity within tissue compartments.⁸

The TME Is Rewired, Not Simply Cleared

Mechanistic insight into these outcomes comes from spatial transcriptomics and multiplex imaging analyses. Following IL-12–armored CAR T-cell treatment, the TME undergoes a striking transformation.⁸

Immunosuppressive FOLR2⁺ macrophages are effectively eliminated and replaced by CXCL9⁺ immunostimulatory macrophages, resulting in a more than 80-fold shift in the balance between suppressive and stimulatory populations. These CXCL9⁺ macrophages exhibit enhanced antigen presentation capacity, increased chemokine production, and activation of pro-inflammatory pathways.

Importantly, this reprogrammed state persists even after contraction of the infused CAR T-cell population. This suggests that the therapeutic effect is not dependent on continued CAR T-cell presence but rather reflects a durable reconfiguration of the immune environment.

In this context, the TME is not merely depleted—it is fundamentally reoriented.

Endogenous Immunity Emerges as the Dominant Effector

One of the most notable findings of this study is that tumor clearance is driven primarily by endogenous immune cells rather than the infused CAR T cells themselves.

Following treatment, there is a marked expansion of activated CD8⁺ T cells, accompanied by a substantial reduction in regulatory T cells and the emergence of memory and stem-like T-cell populations associated with long-term immune control.⁸

Mechanistically, tumor killing is mediated in part through a FAS-dependent pathway. IL-12 signaling promotes upregulation of FAS on tumor cells, enabling apoptosis through engagement by activated endogenous T cells. Knockdown of FAS significantly attenuated therapeutic efficacy, confirming the importance of this axis.⁸

Taken together, these findings suggest that the primary role of the CAR T product is not direct cytotoxicity, but rather the orchestration of an effective endogenous immune response.

Activity Extends Across Tumor Types and Targets

Parallel experiments targeting TREM2⁺ macrophages demonstrated similar patterns of TME remodeling and survival benefit in lung cancer models.⁸ The consistency of these findings across targets and tumor types supports the view that the TAM compartment itself—rather than any single tumor antigen—represents the key therapeutic vulnerability.

Clinical and Translational Perspective

This work carries several important implications for the development of CAR T-cell therapy in solid tumors.

Targeting the TME rather than tumor cells offers a potential solution to antigen heterogeneity and escape, which have limited prior CAR T approaches.¹¹ By focusing on a conserved component of the tumor ecosystem, this strategy may provide a more stable and broadly applicable target.

Equally important is the observation that endogenous T cells mediate the majority of tumor killing. This shifts the therapeutic paradigm toward one in which CAR T cells act as initiators of immune activation, rather than as the sole effectors. From a translational standpoint, this raises the possibility that lower cell doses and shorter persistence may still yield meaningful clinical benefit.⁸

The ability to achieve activity without lymphodepletion is particularly notable. Conditioning chemotherapy remains a significant barrier to CAR T delivery, both in terms of toxicity and logistical complexity.^12,13 A platform that maintains efficacy without this requirement could meaningfully expand access, especially in older or more medically complex patient populations.

Finally, the immune phenotype induced by this therapy—characterized by CXCL9⁺ macrophages, expanded CD8⁺ T cells, and reduced Tregs—closely resembles the microenvironment associated with responsiveness to checkpoint inhibition.¹⁴ This provides a strong rationale for combination strategies.

Safety Considerations and Open Questions

IL-12 remains the primary safety consideration. While localized delivery reduces systemic exposure, its safety profile in humans will require careful evaluation.¹⁰

Additional questions include the durability of macrophage reprogramming over time, the potential for re-establishment of suppressive macrophage populations, and the degree of off-tumor targeting in normal tissue macrophage compartments. The extent to which broader or combinatorial myeloid targeting strategies may enhance efficacy also remains to be explored.

What Comes Next

Further preclinical work in immunocompetent systems will be essential to define safety, pharmacodynamics, and optimal dosing strategies. Early clinical studies will likely focus on tumor types with high macrophage burden and limited treatment options, including ovarian, pancreatic, and lung cancers.

A concurrent study in the same issue of Cancer Cell provides independent validation of this approach using TREM2-directed CAR T cells, supporting the emergence of myeloid-directed CAR T therapy as a distinct and potentially impactful therapeutic class.¹⁵

Bottom Line

Mateus-Tique and colleagues demonstrate that the tumor microenvironment is not a static barrier, but a system that can be actively reshaped. By combining targeted macrophage depletion with immune reprogramming, IL-12–armored CAR T cells convert immunologically cold tumors into environments capable of sustaining endogenous anti-tumor immunity.

The implication is clear: the future of CAR T therapy in solid tumors may depend less on direct tumor cell killing, and more on the ability to precisely guide the immune system toward effective and durable responses.

References

1. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544. doi:10.1056/NEJMoa1707447
2. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399–416. doi:10.1038/nrclinonc.2016.217
3. Pittet MJ, Michielin O, Migliorini D. Clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol. 2022;19(7):402–421. doi:10.1038/s41571-022-00620-6
4. Zilionis R, Engblom C, Pfirschke C, et al. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity. 2019;50(5):1317–1334.e10. doi:10.1016/j.immuni.2019.03.009
5. Molgora M, Esaulova E, Vermi W, et al. TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy. Cell. 2020;182(4):886–900.e17. doi:10.1016/j.cell.2020.07.013
6. Papadopoulos KP, Gluck L, Martin LP, et al. First-in-human study of AMG 820, a monoclonal anti-colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumors. Clin Cancer Res. 2017;23(19):5703–5710. doi:10.1158/1078-0432.CCR-16-3261
7. Gomez-Roca C, Cassier P, Zamarin D, et al. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. J Immunother Cancer. 2022;10(5):e004076. doi:10.1136/jitc-2021-004076
8. Mateus-Tique J, Lakshmi A, Singh B, et al. Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growth. Cancer Cell. 2026;44(3):534–550.e11. doi:10.1016/j.ccell.2025.12.021
9. Tugues S, Burke S, Saez de Guinoa J, et al. New insights into IL-12-mediated tumor suppression. Cell Death Differ. 2015;22(2):237–246. doi:10.1038/cdd.2014.134
10. Lasek W, Zagożdżon R, Jakobisiak M. Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother. 2014;63(5):419–435. doi:10.1007/s00262-014-1523-1
11. Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219–1226. doi:10.1158/2159-8290.CD-18-0442
12. Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4⁺:CD8⁺ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123–2138. doi:10.1172/JCI85309
13. Wang X, Riviere I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics. 2016;3:16015. doi:10.1038/mto.2016.15
14. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275–287. doi:10.1038/nrc.2016.36
15. Yagel G, Bester R, Tsitsiklis A, et al. Tumor-antigen-independent targeting of solid tumors by armored macrophage-directed anti-TREM2 CAR T cells. Cancer Cell. 2026;44(3):511–533.e11. doi:10.1016/j.ccell.2025.11.009